alexa
 
Home News Top generic drug companies in fray for Novartis' brands

Read more interesting news from around the globe with Wealth Doctor App

Google Play
 
Top generic drug companies in fray for Novartis' brands

Top generic drug companies in fray for Novartis' brands

Saturday, April 1, 2017, 8:59 PM

Leading Indian generic drug makers Lupin, Cipla, Zydus Cadila and Sun are eyeing to acquire the respiratory drugs portfolio of Novartis AG that the Swiss giant is seeking to divest. The portfolio of brands on offer could fetch as much as $500 million in a sale. The Novartis portfolio includes top-selling brand TOBI Podhaler, a drug prescribed for symptomatic relief-to-patients suffering from cystic fibrosis.
Read More

Learn to Save, Spend, Invest & Borrow Wisely with our Youtube Channel

Get It now!